

## BIOTECHGATE'S (BTG) COUNTRY PROFILE

Welcome to Biotechgate's Country Profile. The information contained herein has been collected from Venture Valuation's Biotechgate database and is also available to all subscribers at [www.biotechgate.com](http://www.biotechgate.com).




**Country:** Switzerland

**No. of Cantons:** 26

**NO. OF BIOTECH COMPANIES:** 327 (on BTG)

**BIOTECH ONLY FINANCINGS:** USD 165 M (in 2012)


**NO. OF FUNDING ROUNDS:** 12 (in 2012)



### SWITZERLAND AND CANTONS FAST STATS


	Total Biotechs	Biotech Therapeutics and Diagnostics	Biotech R&D Services	Biotech - Other
<b>Switzerland</b>	<b>327</b>	<b>93</b>	<b>171</b>	<b>63</b>
<i>ONLY Cantons with more than 15 companies are listed below</i>				
Zurich	89	29	39	21
Basel Stadt	36	17	16	3
Basel Land	34	6	21	7
Geneva	30	11	14	5
Vaud	23	9	8	6
Bern	22	3	13	6
Tessin	19	3	15	1
Zug	17	5	9	3

### COMPANY OWNERSHIP AND BIOTECH SECTOR BREAKDOWN IN SWITZERLAND





The Swiss biotech landscape is dominated by private companies (80%). Subsidiaries of international companies account for 16% of all biotechs and 4% are publicly listed companies.

Biotechnology companies that focus on the *R & D Services* area are the most prominent in Switzerland representing 52% of all biotechs. The *Therapeutics* segment is also well served with 29% of companies concentrating within this segment. The remaining 19% of biotechs serve other fields.



## SWISS BIOTECH EMPLOYEE NUMBERS AND SOURCE OF FOUNDATION



The majority of Swiss life science companies (74%) employ up to 50 employees. Only 10% of companies employ more than 200 employees.



42% of all Swiss biotechs have been independently founded. A significant number (15%) have also been spun off well known universities such as ETH Zurich and EPF Lausanne. Subsidiaries of international parent companies also feature prominently comprising 12%.

## CATEGORIES AND PRODUCT DEVELOPMENT IN THE SWISS BIOTECH SECTOR

The most significant categories of research in the Swiss biotech field (in descending order) include companies in Services and Supplies (25%), Diagnostic and Analytical Services (19%), Therapeutics (16%) and Contract Research and Manufacturing (14%).




Switzerland has a well developed biotech pipeline. Currently, half of all products in the *therapeutics* category are still in pre-clinical development. However, almost 30% of all products have passed at least Phase I studies and are currently in either Phase II or III.

PRIVATE & PUBLIC FINANCING IN SWISS BIOTECH & MEDTECH CATEGORIES

Top 5 largest financings in Switzerland 2012 (Public & Private)			
COMPANY	SECTOR	TYPE OF ROUND	AMOUNT (USD M)
Biocartis AG	Biotech	Series D	45
Cytos Biotechnology AG	Biotech	Post IPO	44
Endosense	Medtech	Series C	40
GenKyoTex S.A	Biotech	Series C	27
Sensimed AG	Medtech	Series C	18

Total financing value and number of funding rounds 2008 – 2012



Financings in the Swiss *biotech and medtech* landscape have remained within the USD 250 M per year range over the last 3 years. All three of these years were down at least 22% compared to the funding that was raised back in 2009 (USD 323 M). In 2012, there were 24 funding rounds, a figure higher than the preceding four years.

**BIOTECHGATE**  
Your source for life sciences company information

[Get a free trial](#)

[www.biotechgate.com](http://www.biotechgate.com)

**About us:**

**Venture Valuation ([www.venturevaluation.com](http://www.venturevaluation.com))**

Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in biotechnology, med-tech and pharma.

**Biotechgate ([www.biotechgate.com](http://www.biotechgate.com)).**

Biotechgate is a global Life Sciences Database containing over 25'000 company profiles and providing the user with information on available licensing products, financing rounds, key management, technology platforms. It also contains a licensing deals database, all with financial information on the specific deal.

For any questions or comments, please contact the authors Dr. Patrik Frei or Mr. L. Paul Kochman at Venture Valuation.